$PFE Headlines Visa,

New Post Public Reply Private Reply Replies (0) Message Board

Dec 8, 2014 at 10:35 PM

$PFE Headlines

Visa, Goldman Sachs powering Dow to 18,000
4:29 p.m. Dec. 5, 2014
- Tomi Kilgore

Will Santa come to Broad and Wall?
1:54 p.m. Dec. 1, 2014
- The Trading Deck

Dow buy signals push index higher
11:39 a.m. Nov. 24, 2014
- The Trading Deck

Are consumers getting gouged on health care?
9:35 a.m. Nov. 22, 2014
- Russ Britt

AstraZeneca advances in London; pound rises as inflation ticks up
11:59 a.m. Nov. 18, 2014
- Carla Mozee

Zoetis unveils $500 million buyback plan
7:52 a.m. Nov. 18, 2014
- Michael Calia

AstraZeneca forecasts revenue of $45 bln by 2023
2:42 a.m. Nov. 18, 2014
- MarketWatch.com

Updates, advisories and surprises
6:01 p.m. Nov. 17, 2014
- MarketWatch

Urban Outfitters slides after earnings miss expectations
4:43 p.m. Nov. 17, 2014
- Sue Chang

U.K. stocks rise on Draghi stimulus talk; AstraZeneca drops
12:04 p.m. Nov. 17, 2014
- Carla Mozee

Pfizer, Germany’s Merck strike deal to develop cancer tumor treatment
11:05 a.m. Nov. 17, 2014
- Natalia Drozdiak

Pfizer, Germany's Merck to develop tumor treatment
10:22 a.m. Nov. 17, 2014
- MarketWatch.com

Halliburton-Baker Hughes Deal: Antitrust Issues?
9:27 a.m. Nov. 17, 2014
- MarketWatch

Mon., Nov. 17: Pfizer Stock After Pre-Market Drop
9:24 a.m. Nov. 17, 2014
- MarketWatch

Ford may be a buy, but U.S. stocks look stretched vs. the rest of the world
9:11 a.m. Nov. 17, 2014
- Shawn Langlois

Pfizer's stock drops after profit outlook cut
8:04 a.m. Nov. 17, 2014
- Tomi Kilgore

Pfizer's stock falls 1.6% in premarket trade
7:49 a.m. Nov. 17, 2014
- Tomi Kilgore

Pfizer previous EPS guidance was $1.50-$1.59
3:22 a.m. Nov. 17, 2014
- Karen Friar

Pfizer cuts 2014 EPS guidance to $1.40 to $1.49
3:22 a.m. Nov. 17, 2014
- Karen Friar

Pfizer, Merck to jointly develop cancer treatment
3:20 a.m. Nov. 17, 2014
- Karen Friar

Generic EpiPen Could Give These 2 Stocks A Jolt Of Adrenaline

4:48 p.m. Today4:48 p.m. Dec. 8, 2014
- Seeking Alpha

Assessing The Magnitude Of Pfizer's Coming Dividend Increase

3:11 p.m. Today3:11 p.m. Dec. 8, 2014
- Seeking Alpha

Merck Acquiring Cubist, Focusing On Hospital Care

10:48 a.m. Today10:48 a.m. Dec. 8, 2014
- Investors Business Daily

Pfizer Reports Expansion of Rare Disease Research with Establishment of Gene Therapy Platform

7:07 a.m. Today7:07 a.m. Dec. 8, 2014
- benzinga.com

Perky Dow Dividend Dogs Pop Up In December

4:14 a.m. Today4:14 a.m. Dec. 8, 2014
- Seeking Alpha

Health and Tech Funds Step Up

11:06 p.m. Dec. 7, 2014
- The Wall Street Journal Interactive Edition

What Eli Lilly Can Do To Keep Its Amazing Rally Going In 2015

5:07 p.m. Dec. 5, 2014
- Seeking Alpha

Will Someone Take GlaxoSmithKline Out Of Its Misery?

4:11 p.m. Dec. 5, 2014
- Seeking Alpha

The 4 Stocks That Carried the Market on Friday
3:30 p.m. Dec. 5, 2014
- 247WallSt.com

Bayer Doesn’t Look Ready for Animal Magnetism

8:22 a.m. Dec. 5, 2014
- The Wall Street Journal Interactive Edition

Can Albert Einstein's Math Get You To The Finish Line? Retirement Portfolio Quarterly Review

3:57 p.m. Dec. 4, 2014
- Seeking Alpha

Hot Drugmakers Build More Labs, Grab Space In Boston

3:47 p.m. Dec. 4, 2014
- Investors Business Daily

Mylan receives tentative FDA approval for paediatric formulations of abacavir/lamivudine through innovative collaboration with ViiV Healthcare and Clinton Health Access Initiative
11:29 a.m. Dec. 4, 2014
- CNW Group

Dividend Dogs Of Healthcare: A 29.17% Advantage For The 5 Lowest Price High Yield Stocks

9:37 a.m. Dec. 4, 2014
- Seeking Alpha

5 Prime Dividend Dogs Of Healthcare Hound 11% To 45.4% November Upsides

3:40 a.m. Dec. 4, 2014
- Seeking Alpha

Puma Biotechnology Down on Delay in Neratinib NDA Filing - Analyst Blog

5:10 p.m. Dec. 3, 2014
- Zacks.com

Puma Biotech Stock Plunges On Drug Filing Delay

10:43 a.m. Dec. 3, 2014
- Investors Business Daily

Zoetis in a Growing Global Animal Health Industry

10:32 a.m. Dec. 3, 2014
- GuruFocus.com

2014’s Underperforming Large-Cap Stocks That Could Be 2015 Winners
7:37 a.m. Dec. 3, 2014
- 247WallSt.com

Pete Najarian Sees Unusual Options Activity In Pfizer

6:35 a.m. Dec. 3, 2014
- benzinga.com

Spark Therapeutics Announces Gene Therapy Collaboration in Hemophilia B with Pfizer Inc.
8:06 a.m. Today8:06 a.m. Dec. 8, 2014
- PR Newswire - PRF

Pfizer Expands Rare Disease Research with Establishment of Gene
Therapy Platform
8:02 a.m. Today8:02 a.m. Dec. 8, 2014
- BusinessWire - BZX

iTeos Therapeutics Announces License and Collaboration with Pfizer Inc. for Discovery and Development of Cancer Immunosuppression Targets
2:30 a.m. Today2:30 a.m. Dec. 8, 2014
- PR Newswire - PRF

Tenet Healthcare Names Dr. Freda C. Lewis-Hall to Board of Directors
4:00 p.m. Dec. 4, 2014
- BusinessWire - BZX

Mylan receives tentative FDA approval for paediatric formulations of abacavir/lamivudine through innovative collaboration with ViiV Healthcare and Clinton Health Access Initiative
11:29 a.m. Dec. 4, 2014
- PR Newswire - PRF

Mylan receives tentative FDA approval for pediatric formulations of abacavir/lamivudine through innovative collaboration with ViiV Healthcare and Clinton Health Access Initiative
10:00 a.m. Dec. 4, 2014
- PR Newswire - PRF

Phase 3 Results Published in TheNew England Journal of
Medicine Show Superiority of Pfizer’s XALKORI® (crizotinib)
Compared to Platinum-Based Chemotherapy in Previously Untreated Patients
With ALK-Positive Advanced Non-Small Cell Lung Cancer
5:07 p.m. Dec. 3, 2014
- BusinessWire - BZX

Diplomat selected as a limited-distribution pharmacy partner by Pfizer; Diplomat to dispense Xalkori®, Bosulif®, Sutent® and Inlyta®
4:37 p.m. Dec. 3, 2014
- PR Newswire - PRF

Lpath Completes Enrollment in its Phase 2 Clinical Trial of iSONEP for Wet Age-Related Macular Degeneration
4:05 p.m. Dec. 2, 2014
- PR Newswire - PRF

BioClinica Names Dr. John Hubbard Chief Executive Officer
9:14 a.m. Dec. 1, 2014
- PR Newswire - PRF

Pfizer Completes Acquisition of Baxter’s Marketed Vaccines
7:30 a.m. Dec. 1, 2014
- BusinessWire - BZX

TechNavio Names Pfizer, Merck, F. Hoffmann-La Roche as Top Companies in
the Global Human Growth Hormone Market
1:15 p.m. Nov. 20, 2014
- BusinessWire - BZX

Sanguine's Mobile Application to Assist Recruitment for Pfizer Inc. Chronic Pain Research
9:00 a.m. Nov. 18, 2014
- PR Newswire - PRF

TRUMENBA® (Meningococcal Group B Vaccine) is
Now Available
8:30 a.m. Nov. 18, 2014
- BusinessWire - BZX

Novel Agreement Expands Access to Pfizer’s Contraceptive, Sayana®
Press, for Women Most in Need in the World’s Poorest Countries
11:00 a.m. Nov. 13, 2014
- BusinessWire - BZX

Pfizer Highlights Leadership in Rheumatology and Inflammation with
Data to be Presented at the ACR/ARHP 2014 Annual Meeting
8:01 a.m. Nov. 12, 2014
- BusinessWire - BZX

Insider Trading Recap for AK Steel, Pfizer, Chesapeake Energy, Plug Power, Twitter, and RF Micro Devices
8:45 a.m. Nov. 11, 2014
- PR Newswire - PRF

Amy Schulman Joins The Board Of Directors Of Blue Buffalo
9:34 a.m. Nov. 10, 2014
- PR Newswire - PRF

Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At
Healthcare Conference
11:00 a.m. Nov. 5, 2014
- BusinessWire - BZX

Pharma Stocks on our Radar - Pfizer, Merck, Sanofi, Shire, and Zogenix
8:55 a.m. Nov. 4, 2014
- PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Scams vs Identity Theft: Trauma's Dark Impact Revealed

Facing the Dark Reality of Scams and Identity Theft Imagine facing a bleak financial horizon because of scams and identity theft, but the weight on your soul ain't about just numbers. That's what the Identity Theft Resource Center's 2026 Consumer Impact Report brings to light. We're talking about massive mental and emotional whirlwinds, way beyond mere dollars and cents....

kidSTREAM Museum Welcomes Carina Reeves as New CEO

Carina Reeves Takes the Helm at kidSTREAM You know how it goes—sometimes you need fresh leadership to steer the ship. That's exactly what's happening over at kidSTREAM Children's Museum. They've appointed Carina Reeves as their President and CEO after a nationwide hunt. This ain't just another CEO shuffle; it marks a pivotal moment as kidSTREAM inches closer to its...

FirstEnergy's New Tech to Bolster Pennsylvania Grid

Electricity Demand Spurs Grid Innovation The winds of change are blowing across Pennsylvania's power grid. FirstEnergy Transmission's (NYSE:FE) subsidiary, Keystone Appalachian Transmission Company (KATCo), is diving into a significant federally funded project to reinforce grid reliability. With electricity demand on an upward trajectory, Pennsylvania and beyond need...

Infection Control Market Set for Explosive Growth by 2031

Untangling the Surge in Infection Control Demand Lately, it's like every healthcare joint worldwide is scrambling for better infection control. We're talking about a market poised to jump from a whopping USD 58.5 billion in 2026 to USD 80.2 billion by 2031—a tidy 37% uptick. That change, brewing at a 6.5% CAGR, speaks volumes about where the industry's heading. What's...

Evotec SE to Release Q3 Results: What to Expect

Anticipation Builds Around Evotec's Q3 2026 Results It's that time again when everyone's tightening their belts in anticipation of another earnings feed. On November 5, Evotec SE is dropping their results for the first nine months of this whirlwind year. Right out of Germany, Hamburg, they're gearing up for a webcast and conference call where all eyes, or should I say...

Ryde Group Faces Class Action: Key Investor Takeaways

Ryde Group's Tumble: More Than Just Market Volatility When RYDE shares nosedived like a lead balloon, it wasn't due to a market hiccup—it was a darn mess fueled by alleged manipulation. At the heart of this crash are accusations of a blatant pump-and-dump scheme that allegedly swindled investors out of millions. Pump-and-Dump: The Dirty Mechanics This ain't your regular...

Life Time's Q3 2026 Results Highlight Solid Growth

Life Time Rolls On With Strong Q3 Performance Sometimes the market hands you pure gold, and that's what Life Time (NYSE: LTH) has right now. They didn't just have a decent quarter; they outright nailed it with a $893.5 million total revenue haul—a hefty 14.2% rise from the prior year. What's driving this ship? Solid growth in membership dues and dynamic personal...

AskGamblers Unveils Tool for Casino Complaints

A Fresh Move in the Casino World AskGamblers has made a move that might just change the game for online bettors. They’ve rolled out a new casino complaints dashboard designed to revolutionize how players raise issues with casinos. Sure, the gambling world is no stranger to complaints, and it's about time someone in the sector paid attention to airing dirty laundry in a...

Smirnoff Launches Marvel Event with $12.99 Offer

Smirnoff's Bold Move to Ride Marvel's Coattails Here we are, watching a vodka brand hitch its wagon to a Hollywood juggernaut. Smirnoff has announced a fan experience to toast Marvel Studios' "Avengers: Doomsday." Of course, this isn't just about clinking glasses; it's a marketing stunt dressed in superhero tights. The impressive part? They’re selling the razzmatazz for...

SELCO and Numerica Unite: A Merger That's All Heart

Big Merger in Credit Union World: SELCO and Numerica Sometimes, it ain't all about dollars and cents. That's the vibe I'm picking up from this merger of equals between SELCO Community and Numerica Credit Unions. This isn't a Wall Street hustle, it's hometown hustle—where the biggest reward isn't just a fat line at the bottom but seeing your community thrive. The Vision...